Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 7/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.59 |
| ▸ | AGT | P01019 | 2/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9090 | 0.95 | AGTR2 (0.65) | GP6AGTR1AGTR2AGT | |
| SCHEMBL9424364 | 0.90 | AGTR1 (0.56) | GP6AGTR1AGTR2AGT | |
| SCHEMBL9424366 | 0.90 | AGTR1 (0.56) | GP6AGTR1AGTR2AGT | |
| SCHEMBL9030644 | 0.88 | AGTR2 (0.67) | GP6AGTR1AGTR2AGT | |
| SCHEMBL9567372 | 0.87 | AGT (0.56) | GP6AGTR1AGTR2AGT | |
| SCHEMBL498022 | 0.87 | AGTR2 (0.63) | AGTR1AGTR2AGT | |
| SCHEMBL610 | 0.86 | AGTR1 (0.62) | AGTR1AGTR2AGTABCC4ABCB11 | |
| SCHEMBL16950035 | 0.86 | GP6 (0.66) | GP6AGTR1AGTR2ABCC4ABCB11 | |
| SCHEMBL9029527 | 0.86 | AGTR2 (0.64) | GP6AGTR1AGTR2AGT | |
| SCHEMBL9314520 | 0.85 | AGTR1 (0.57) | AGTR1AGTR2AGTABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146963-B1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-7858651-B2 | Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof | SHANGHAI ALLIST PHARMACEUTICAL, INC. (CN) | 2010-12-28 | — | — | US | disclosed |
| EP-2250168-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009099853-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1833801-B9 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2009-02-25 | — | — | EP | disclosed |
| EP-2027091-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - Portela & Ca., S.A. (PT) | 2009-02-25 | — | — | EP | disclosed |
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-02-05 | — | — | US | disclosed |
| EP-1833801-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2008-06-04 | — | — | EP | disclosed |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | disclosed |
| WO-2007117165-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2007-10-18 | — | — | WO | disclosed |
| EP-0535465-A1 | Cyclic substituted imidazolylpropen acid derivatives as angiotensin II antagonists | BAYER AG (DE) | 1993-04-07 | — | — | EP | disclosed |
| EP-0535463-A1 | Imidazolpropen acid derivatives as angiotensin II antagonists | BAYER AG (DE) | 1993-04-07 | — | — | EP | disclosed |
| US-5164407-A | Hypotensive agents | MERCK & CO., INC. (US) | 1992-11-17 | — | — | US | disclosed |
| US-5155118-A | Administering angiotensin inhibitor | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153197-A | Treatment of hypertension with angiotensin II blocking imidazoles | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| US-5138069-A | Treating hypertension and congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| US-5128355-A | Hypotensive | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0407102-A1 | Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-09 | — | — | EP | disclosed |
| EP-0324377-A2 | Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| WO-1989006233-A1 | ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036505-A1 | Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof | AGTR2, AGTR1, REN | GP6 2440/4885AGTR1 2/4885AGTR2 1/4885 |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | AGTR1, REN, AGT | GP6 2755/4885AGTR1 1/4885AGTR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.